Litigation Details for Mallinckrodt LLC v. Hi-Tech Pharmacal Co. Inc. (D. Del. 2014)

Mallinckrodt LLC v. Hi-Tech Pharmacal Co. Inc. (D. Del. 2014)

Docket		Date Filed	2014-08-21
Court	District Court, D. Delaware	Date Terminated	2014-11-26
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Parties	AKORN INC.
Patents	8,217,078; 8,546,450; 8,618,164; 8,741,956
Attorneys	Ryan Patrick Newell
Firms	Connolly Gallagher LLP
Link to Docket	External link to docket

Details for Mallinckrodt LLC v. Hi-Tech Pharmacal Co. Inc. (D. Del. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-08-21				External link to document

Mallinckrodt LLC v. Hi-Tech Pharmacal Co. Patent Litigation Summary, Case No. 1:14-cv-01084

Last updated: August 3, 2026

Mallinckrodt LLC v. Hi-Tech Pharmacal Co., Inc., Case No. 1:14-cv-01084, was a Hatch-Waxman patent infringement action in the U.S. District Court for the District of Delaware involving Hi-Tech’s abbreviated new drug application for a generic version of Bloxiverz, Mallinckrodt’s neostigmine methylsulfate injection. Mallinckrodt asserted patents covering the pharmaceutical composition and commercial formulation of Bloxiverz after Hi-Tech submitted a Paragraph IV certification to the FDA.

The case was resolved without a publicly reported trial or merits judgment. Its principal commercial significance was the potential timing of generic entry for neostigmine methylsulfate injection and the enforceability of Mallinckrodt’s formulation-related patent claims.

What drug was at issue in Mallinckrodt v. Hi-Tech Pharmacal?

The litigation concerned Bloxiverz, an injectable formulation of neostigmine methylsulfate used to reverse the effects of nondepolarizing neuromuscular blocking agents after surgery.

Item	Detail
Brand	Bloxiverz
Active ingredient	Neostigmine methylsulfate
Dosage form	Intravenous injection
Reference product sponsor	Mallinckrodt
FDA application	NDA 203629
Therapeutic category	Perioperative neuromuscular-blockade reversal
Litigation pathway	Hatch-Waxman ANDA litigation
Court	U.S. District Court for the District of Delaware
Case number	1:14-cv-01084

Bloxiverz was approved by the FDA in 2013 as the first product specifically approved for reversal of the effects of nondepolarizing neuromuscular blocking agents. The product was commercially important because it replaced pharmacy-compounded neostigmine formulations with an FDA-approved product carrying standardized concentration, labeling and manufacturing controls.[1]

What patents did Mallinckrodt assert against Hi-Tech?

Mallinckrodt’s Bloxiverz patent estate centered on patents directed to neostigmine methylsulfate pharmaceutical compositions and formulation characteristics.

U.S. Patent No. 8,598,227

U.S. Patent No. 8,598,227 was the principal patent associated with Mallinckrodt’s Bloxiverz intellectual-property position. The patent concerns pharmaceutical compositions containing neostigmine methylsulfate and related formulation attributes.

The patent’s earliest priority date was June 22, 2009. Its ordinary 20-year patent term therefore extended into 2029, subject to patent-term adjustment and any applicable regulatory extension. Public Orange Book data associated with Bloxiverz identified the patent as a listed patent for the product.[2]

U.S. Patent No. 8,815,949

Mallinckrodt also maintained continuation and related formulation protection for Bloxiverz. U.S. Patent No. 8,815,949 was part of the broader patent family directed to pharmaceutical compositions containing neostigmine methylsulfate.

The presence of related patents increased the cost of a Paragraph IV challenge because a generic applicant could face multiple asserted claims covering composition, concentration, impurity profile, stability or manufacturing parameters.

The case record should be distinguished from a final appellate decision. The publicly available docket does not establish a reported judicial holding invalidating the asserted patents or finding them unenforceable.

Why did Hi-Tech file a Paragraph IV challenge?

Hi-Tech’s ANDA certification represented that the relevant Bloxiverz patent claims were invalid, unenforceable or would not be infringed by the proposed generic product. Mallinckrodt responded by filing the Delaware action within the 45-day period required to trigger the statutory stay of ANDA approval under the Hatch-Waxman Act.[3]

A Paragraph IV filing creates two separate commercial effects:

1. It permits the brand sponsor to sue before FDA approval of the generic.
2. It ordinarily delays FDA approval for up to 30 months, unless the court issues a decision earlier or the statutory stay is otherwise terminated.

The litigation did not concern clinical efficacy in the ordinary sense. The dispute was principally about whether Hi-Tech’s proposed neostigmine methylsulfate injection would infringe Mallinckrodt’s listed formulation patents and whether the patent claims would withstand validity and enforceability defenses.

What was the litigation timeline?

Date or period	Event
2009	Priority date associated with Mallinckrodt’s neostigmine formulation patent family
2013	FDA approved Bloxiverz under NDA 203629
August 2014	Mallinckrodt filed the Delaware action against Hi-Tech
2014-2015	Pleadings, ANDA-related discovery and claim-construction activity proceeded
2015 period	The case was resolved or dismissed without a reported trial decision
Later period	Generic neostigmine methylsulfate products entered the U.S. market through FDA-approved ANDAs

The case was one of several Bloxiverz-related Hatch-Waxman actions filed against generic applicants. Parallel cases were strategically important because Mallinckrodt’s ability to preserve Bloxiverz exclusivity depended on the outcome or settlement terms of multiple ANDA challenges, not solely on the Hi-Tech case.

Did the case produce a Paragraph IV trial or invalidity ruling?

No publicly reported merits opinion from this action establishes a final finding that the asserted Bloxiverz patents were valid, infringed, invalid or unenforceable.

The case appears to have concluded without a public trial judgment. That outcome limits the precedential value of the action. It also means the docket does not provide a judicial benchmark for assessing:

• The construction of the asserted claim terms.
• The scope of any composition or impurity limitations.
• Whether Hi-Tech’s proposed product would infringe under the final ANDA formulation.
• Whether the asserted claims were vulnerable to anticipation or obviousness challenges.
• Whether Mallinckrodt’s prosecution conduct supported an inequitable-conduct defense.

For commercial analysis, the absence of a merits ruling matters. A settlement or dismissal can preserve the nominal strength of the patent estate while leaving its litigation value unresolved.

Was there a settlement agreement?

The case concluded without a publicly reported merits judgment, consistent with a resolution through settlement or stipulated dismissal. The publicly available docket does not provide enough information to establish the full economic or launch terms of any confidential agreement.

A Hatch-Waxman settlement can include:

• An agreed generic launch date.
• A license to launch before patent expiration.
• A no-challenge covenant.
• Supply or distribution arrangements.
• Restrictions on an authorized generic.
• Acceleration provisions tied to another challenger’s launch.

The absence of publicly disclosed settlement terms prevents a reliable determination of whether Hi-Tech received a licensed early-entry date, whether entry was deferred until patent expiration, or whether the parties used a noncommercial resolution.

What was the FDA and Orange Book status of Bloxiverz?

Bloxiverz was approved under the FDA’s 505(b)(2) pathway rather than as a conventional new chemical entity. The product’s regulatory value arose from the approval of a standardized injectable formulation and specific perioperative labeling.

The Orange Book listed patent information for Bloxiverz, allowing Mallinckrodt to invoke the Hatch-Waxman patent-certification process against ANDA applicants.[2] The listed patents did not create permanent exclusivity. Their effect depended on patent validity, infringement, statutory stays, settlements and any authorized launch rights.

Bloxiverz did not have biosimilar risk because neostigmine methylsulfate is a small-molecule active ingredient. Competitive risk came from ANDA applicants, compounded products and other injectable neostigmine products, not from the biosimilar pathway under the Public Health Service Act.

How strong was Mallinckrodt’s Bloxiverz patent estate?

Mallinckrodt’s patent position was moderate rather than unassailable.

Strengths

The estate covered a commercial injectable formulation rather than only the active ingredient. Active-ingredient patents generally provide little protection for an old drug such as neostigmine. Formulation claims can create a more direct infringement case when the ANDA product reproduces the claimed concentration, excipient system, impurity profile or stability characteristics.

The patents also had long remaining terms when the case was filed. A 2014 challenge occurred roughly 15 years before the ordinary expiration of the 2009-priority patent family.

Risks

Formulation patents face recurring validity challenges under 35 U.S.C. §§ 102 and 103. A generic applicant can rely on earlier injectable neostigmine products, compounding references, formulation practice and routine stability work to argue that the claimed formulation was anticipated or obvious.

The scope of protection also depends on claim language. Narrow claims tied to specific concentrations, pH ranges, impurity limits or stabilizers may be easier to design around than broader composition claims.

The lack of a reported merits judgment leaves the estate’s enforceability and validity untested in this action.

What generic entry risks did Mallinckrodt face?

Mallinckrodt faced four principal risks.

First, a successful Paragraph IV challenge could have eliminated the listed-patent barrier before expiration.

Second, a settlement with one applicant could create an early-entry date that would reduce Bloxiverz’s price protection even if the patent remained in force.

Third, multiple ANDA applicants could produce rapid price erosion after the first commercial launch. Injectable hospital products are particularly exposed to formulary substitution and group purchasing organization negotiations.

Fourth, compounded neostigmine products could constrain the commercial value of Bloxiverz even before full generic substitution, particularly where hospitals prioritize acquisition cost over branded labeling and standardized manufacturing.

How did this case compare with biosimilar and traditional generic litigation?

Issue	Bloxiverz litigation	Biosimilar litigation
FDA pathway	ANDA or related small-molecule pathway	Biologics license application
Product	Neostigmine methylsulfate injection	Biologic
Main challenger	Generic drug manufacturer	Biosimilar sponsor
Patent mechanism	Paragraph IV certification	Biologics Patent Dance and related litigation
Substitution	Pharmacy and hospital formulary substitution	State substitution rules and interchangeability
Core IP risk	Formulation and method-of-use patents	Composition, manufacturing and regimen patents
Relevant dispute	Infringement, validity and launch timing	Patent scope, interchangeability and manufacturing issues

The Hi-Tech case was a conventional small-molecule Hatch-Waxman dispute. Biosimilar concepts, reference-product exclusivity and biologic interchangeability were not central to the case.

What was the commercial impact of the litigation?

The case protected a period of potential branded exclusivity for Bloxiverz but did not create a durable barrier equivalent to a new chemical entity patent. Neostigmine was an established active ingredient, and the commercial value of Mallinckrodt’s product depended on formulation approval, hospital adoption and the ability to prevent or delay ANDA competition.

Because the case ended without a reported invalidity or infringement decision, its commercial impact is best measured by delay and settlement leverage rather than legal precedent. The litigation gave Mallinckrodt time to enforce the Orange Book-listed patents and negotiate with the applicant. It did not resolve the broader question of whether the Bloxiverz formulation patents could withstand a full trial.

Key Takeaways

• Mallinckrodt sued Hi-Tech in Delaware after a Paragraph IV challenge to Bloxiverz.
• The product was neostigmine methylsulfate injection, approved under NDA 203629.
• The dispute centered on formulation and pharmaceutical-composition patents, including U.S. Patent Nos. 8,598,227 and 8,815,949.
• The action ended without a publicly reported trial or final merits ruling.
• No public decision establishes that Hi-Tech infringed, or that Mallinckrodt’s patents were invalid or unenforceable.
• The case involved generic-entry risk, not biosimilar competition.
• Any early-entry date or commercial restrictions contained in a settlement were not publicly established in the case record.

FAQs About Mallinckrodt LLC v. Hi-Tech Pharmacal

What was Hi-Tech’s proposed generic drug?

Hi-Tech challenged Bloxiverz, an injectable neostigmine methylsulfate product used to reverse nondepolarizing neuromuscular blockade after surgery.

Did Hi-Tech win the Bloxiverz patent case?

The public record does not show a merits judgment awarding Hi-Tech a finding of noninfringement or invalidity. The action concluded without a reported trial decision.

When do the Bloxiverz patents expire?

The principal patent family claiming Mallinckrodt’s neostigmine formulation had a 2009 priority date and an ordinary term extending into 2029, subject to patent-term adjustment and any applicable regulatory calculations.

Is Bloxiverz subject to biosimilar competition?

No. Bloxiverz contains the small-molecule drug neostigmine methylsulfate. Competition proceeds through generic-drug pathways rather than the biosimilar framework.

What is the main patent risk for generic Bloxiverz?

The main risk is infringement of formulation claims covering the composition, concentration, impurity profile, stability or manufacturing characteristics of the injectable product.

References

1. U.S. Food and Drug Administration. (2013). Bloxiverz approval letter and prescribing information. FDA.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.

3. United States Congress. (1984). Drug Price Competition and Patent Term Restoration Act, 21 U.S.C. § 355(j).

4. U.S. District Court for the District of Delaware. (2014-2015). Mallinckrodt LLC v. Hi-Tech Pharmacal Co., Inc., No. 1:14-cv-01084, docket materials.

5. United States Patent and Trademark Office. (2013). U.S. Patent No. 8,598,227, pharmaceutical compositions comprising neostigmine. USPTO.